The BCL-2 protein is the direct target of Venetoclax (VTC) (ABT-199), a selective BCL-2 inhibitor that alters the mitochondrial apoptotic pathway and causes tumor cell death (4, 5). The gene discussed is BCL2; the disease is neoplasm.